Trial record 1 of 3 for:    LGX818 AND Colorectal Cancer
Previous Study | Return to List | Next Study

Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Array BioPharma Identifier:
First received: October 30, 2012
Last updated: February 11, 2016
Last verified: February 2016
This study will assess the safety and efficacy of LGX818 when combined with cetuximab or combined with cetuximab and BYL719 in patients with BRAF mutant metastatic colorectal cancer

Condition Intervention Phase
Colorectal Cancer
Drug: LGX818
Drug: Cetuximab
Drug: BYL719
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase lb/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer

Resource links provided by NLM:

Further study details as provided by Array BioPharma:

Primary Outcome Measures:
  • Incidence rate of dose-limiting toxicities [ Time Frame: 1.5 years ] [ Designated as safety issue: Yes ]
    Phase I

  • Progression free survival [ Time Frame: 2.5 years ] [ Designated as safety issue: No ]
    Phase II

Secondary Outcome Measures:
  • Incidence and severity of adverse events [ Time Frame: 2.5 years ] [ Designated as safety issue: Yes ]
  • Plasma concentration [ Time Frame: 1.5 years ] [ Designated as safety issue: No ]
  • Overall response rate [ Time Frame: 2.5 years ] [ Designated as safety issue: No ]
  • Duration of response [ Time Frame: 2.5 years ] [ Designated as safety issue: No ]
  • Time to response [ Time Frame: baseline, 2 years ] [ Designated as safety issue: No ]
  • Progression free survival [ Time Frame: 1.5 years ] [ Designated as safety issue: No ]
    Phase Ib

  • Overall survival [ Time Frame: 3 years ] [ Designated as safety issue: No ]
    Phase II

  • Baseline molecular status of potential predictive markers of tumor response or resistance [ Time Frame: 2.5 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 150
Study Start Date: November 2012
Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LGX818 + cetuximab Drug: LGX818 Drug: Cetuximab
Experimental: LGX818 + BYL719 + cetuximab Drug: LGX818 Drug: Cetuximab Drug: BYL719


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Metastatic colorectal cancer
  • Progression after at least one prior standard of care regimen or be intolerant to irinotecan-based regimens
  • Life expectancy ≥ 3 months
  • ECOG performance status ≤ 2

Exclusion Criteria:

  • Symptomatic or untreated leptomeningeal disease
  • Symptomatic brain metastasis
  • Patients with clinically manifested diabetes
  • Acute or chronic pancreatitis
  • Clinically significant cardiac disease

Other protocol-defined inclusion/exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01719380

  Show 30 Study Locations
Sponsors and Collaborators
Array BioPharma
Study Director: Array BioPharma 303-381-6604
  More Information

Responsible Party: Array BioPharma Identifier: NCT01719380     History of Changes
Other Study ID Numbers: CLGX818X2103  2012-002138-35 
Study First Received: October 30, 2012
Last Updated: February 11, 2016
Health Authority: United States: Food and Drug Administration

Keywords provided by Array BioPharma:
Open-label dose escalation; BRAF inhibitor; LGX818; PI3K inhibitor; BYL719; EGFR; cetuximab; metastatic colorectal cancer; KRAS; BRAF; V600

Additional relevant MeSH terms:
Colorectal Neoplasms
Digestive System Neoplasms
Gastrointestinal Neoplasms
Intestinal Neoplasms
Neoplasms by Site
Colonic Diseases
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases
Antineoplastic Agents processed this record on May 26, 2016